Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Vesalius Biocapital Partners

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 56
Average round size
info
The average size of a deal this fund participated in
$22M
Portfolio companies 32
Rounds per year 3.29
Lead investments 14
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Exits 6
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

Vesalius Biocapital Partners appeared to be the VC, which was created in 2007. The company was established in Europe in Luxembourg. The main department of described VC is located in the Strassen.

The higher amount of exits for fund were in 2014. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 5 - 10 millions dollars. Comparing to the other companies, this Vesalius Biocapital Partners performs on 9 percentage points less the average number of lead investments. The top activity for fund was in 2011. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Genkyotex, Promethera Biosciences, Tonic App For fund there is no match between the location of its establishment and the land of its numerous investments - Belgium. The fund has exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Machine Learning, Biopharma.

Besides them, we counted 3 critical employees of this fund in our database.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Vesalius Biocapital Partners, startups are often financed by High-Tech Gru00fcnderfonds, VC Fonds Technologie Berlin, S.R.I.W.. The meaningful sponsors for the fund in investment in the same round are S.R.I.W., Limburgse Reconversie Maatschappij, High-Tech Gru00fcnderfonds. In the next rounds fund is usually obtained by SFPI-FPIM, S.R.I.W., Lumira Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vesalius Biocapital Partners:
Typical Co-investors
Vesalius Biocapital Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vesalius Biocapital Partners:

Funds with similar focus

Funds from Luxembourg
Funds with similar focus located in Luxembourg:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Caresyntax

Analytics
Artificial Intelligence
Data Visualization
Health Care
Health Insurance
Hospital
Information Technology
Machine Learning
Medical
Software
$80M15 Aug 2024 Boston, Massachusetts, United States

HepaRegeniX

Biotechnology
Health Care
Life Science
Therapeutics
$17M10 Jul 2024 Ulm, Baden-Württemberg, Germany

inHEART

Biotechnology
Medical Device
Software
$11M06 May 2024 France, New Aquitaine, France

Tonic App

Database
Health Care
Hospital
Medical
Mobile Apps
$12M26 Mar 2024 Portugal, Portugal

Memo Therapeutics

Biotechnology
Collaboration
$27M02 Nov 2023 Zurich, Zurich, Switzerland

Catalym

Therapeutics
$59M22 Nov 2022 Munich, Bavaria, Germany

Scenic Biotech

Biometrics
Biotechnology
Collaborative Consumption
Life Science
$33M10 Mar 2022 Amsterdam, North Holland, Netherlands

Memo Therapeutics

Biotechnology
Collaboration
$25M16 Feb 2022 Zurich, Zurich, Switzerland

Rejuvenate Biomed

Health Care
$18M12 Oct 2021 Oost-Vlaanderen, East Flanders, Belgium
News
Caresyntax Raises $100M in Series C Funding

– Caresyntax from Boston is a digital surgery platform that provides actionable insights to improve patient outcomes.
– The company closed a $100m Series C funding.
– The round was led by PFM Health Sciences LP and included participation from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, as well as current investors IPF Partners, the Relyens Group, and Surgical.
– The new investment will be used to accelerate the company’s global expansion and development of new products.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vesalius Biocapital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 56
Average round size 22M
Rounds per year 3.29
Peak activity year 2024
Lead investments 14
Follow on index 0.43
Exits 6
Group Appearance index 0.98

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Caresyntax

Analytics
Artificial Intelligence
Data Visualization
Health Care
Health Insurance
Hospital
Information Technology
Machine Learning
Medical
Software
$80M15 Aug 2024 Boston, Massachusetts, United States

HepaRegeniX

Biotechnology
Health Care
Life Science
Therapeutics
$17M10 Jul 2024 Ulm, Baden-Württemberg, Germany

inHEART

Biotechnology
Medical Device
Software
$11M06 May 2024 France, New Aquitaine, France

Tonic App

Database
Health Care
Hospital
Medical
Mobile Apps
$12M26 Mar 2024 Portugal, Portugal

Memo Therapeutics

Biotechnology
Collaboration
$27M02 Nov 2023 Zurich, Zurich, Switzerland

Catalym

Therapeutics
$59M22 Nov 2022 Munich, Bavaria, Germany

Scenic Biotech

Biometrics
Biotechnology
Collaborative Consumption
Life Science
$33M10 Mar 2022 Amsterdam, North Holland, Netherlands

Memo Therapeutics

Biotechnology
Collaboration
$25M16 Feb 2022 Zurich, Zurich, Switzerland

Rejuvenate Biomed

Health Care
$18M12 Oct 2021 Oost-Vlaanderen, East Flanders, Belgium
Crunchbase icon

Content report

The following text will be sent to our editors: